Lantern Pharma Inc.

LTRN

Healthcare|Biotechnology|US

$0.57

+0.04 (+6.75%)

Cash / Share

$0.59

Next Earnings Report

Nov 11, 2026

EPS est. -$0.35

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Sep 30, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Dec 2026

Est. completion

P2Adenocarcinoma of Lung

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

NCT05456256n=90

Nov 2028

Est. completion

P1Relapsed or Refractory Lymphomas

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503n=110

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026

P1P2

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265

Recent Press Releases

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Oct 7, 2026 · Business Wire

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Sep 30, 2026 · Business Wire

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

Sep 29, 2026 · Business Wire

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

Sep 23, 2026 · Business Wire

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

Sep 22, 2026 · Business Wire

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

Sep 17, 2026 · Business Wire

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026 · Business Wire

SEC Filings (50)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 21, 2026	ARS	Annual report to holders	Document Index
Oct 19, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Oct 13, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 8, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Oct 1, 2026	8-K	Material event	Document Index
Sep 30, 2026	8-K	Material event	Document Index
Sep 30, 2026	424B5	Offering prospectus	Document Index
Sep 24, 2026	8-K	Material event	Document Index
Sep 23, 2026	8-K	Material event	Document Index
Aug 14, 2026	8-K	Material event	Document Index
Aug 14, 2026	10-Q	Quarterly report	Document Index
Aug 4, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 3, 2026	8-K	Material event	Document Index
Jul 23, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jun 18, 2026	EFFECT		Document Index
Jun 12, 2026	S-1	IPO / offering registration	Document Index
Jun 2, 2026	8-K	Material event	Document Index
May 21, 2026	D		Document Index
May 15, 2026	SC 13D/A	Activist / 5%+ stake	Document Index
May 15, 2026	8-K	Material event	Document Index
May 15, 2026	10-Q	Quarterly report	Document Index
May 14, 2026	8-K	Material event	Document Index
May 14, 2026	424B5	Offering prospectus	Document Index
Apr 30, 2026	10-K/A	Annual report	Document Index
Apr 16, 2026	SC 13D/A	Activist / 5%+ stake	Document Index
Apr 10, 2026	8-K	Material event	Document Index
Apr 3, 2026	SC 13G	Passive 5%+ stake	Document Index
Mar 30, 2026	424B5	Offering prospectus	Document Index
Mar 30, 2026	10-K	Annual report	Document Index
Mar 30, 2026	8-K	Material event	Document Index
Feb 23, 2026	SC 13D/A	Activist / 5%+ stake	Document Index
Jan 23, 2026	8-K	Material event	Document Index
Nov 13, 2025	8-K	Material event	Document Index
Nov 12, 2025	10-Q	Quarterly report	Document Index
Sep 23, 2025	8-K	Material event	Document Index
Aug 13, 2025	8-K	Material event	Document Index
Aug 13, 2025	10-Q	Quarterly report	Document Index
Aug 11, 2025	ARS	Annual report to holders	Document Index
Aug 8, 2025	DEF 14A	Proxy / shareholder vote	Document Index
Jul 29, 2025	8-K	Material event	Document Index